{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:10:53Z","timestamp":1792602653188,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10072-022-06363-7","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T11:05:22Z","timestamp":1661857522000},"page":"6707-6717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Inflammatory markers and depression in Parkinson\u2019s disease: a systematic review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-9793","authenticated-orcid":false,"given":"Luis Guilherme","family":"Ramanzini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds Fernando Muniz","family":"Camargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Oliveira Freitas","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Vargas","family":"Bochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"6363_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LML De Lau","year":"2006","unstructured":"De Lau LML, Breteler MMB (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5:525\u2013535. https:\/\/doi.org\/10.1016\/S1474-4422(06)70471-9","journal-title":"Lancet Neurol"},{"key":"6363_CR2","doi-asserted-by":"publisher","unstructured":"Assogna F, Cravello L, Caltagirone C et al (2011) Anhedonia in Parkinson\u2019s disease: a systematic review of the literature. Mov Disord 26(10):1825\u20131834. https:\/\/doi.org\/10.1002\/MDS.23815","DOI":"10.1002\/MDS.23815"},{"key":"6363_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.PARKRELDIS.2016.03.021","volume":"28","author":"F Assogna","year":"2016","unstructured":"Assogna F, Cravello L, Orfei MD et al (2016) Alexithymia in Parkinson\u2019s disease: a systematic review of the literature. Parkinsonism Relat Disord 28:1\u201311. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2016.03.021","journal-title":"Parkinsonism Relat Disord"},{"key":"6363_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/MDS.10387","volume":"18","author":"AF Leentjens","year":"2003","unstructured":"Leentjens AF, den Akker MV, Metsemakers JFM, ak, (2003) Higher incidence of depression preceding the onset of Parkinson\u2019s disease: a register study. Mov Disord 18:414\u2013418. https:\/\/doi.org\/10.1002\/MDS.10387","journal-title":"Mov Disord"},{"key":"6363_CR5","doi-asserted-by":"publisher","unstructured":"Caig G, Tolosa E (2009) When does Parkinson\u2019s disease begin? Mov Disord 24(Suppl 2): S656\u2013S664.\u00a0https:\/\/doi.org\/10.1002\/MDS.22672","DOI":"10.1002\/MDS.22672"},{"key":"6363_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.20324","volume":"20","author":"MA Hely","year":"2005","unstructured":"Hely MA, Morris JGL, Reid WGJ, Trafficante R (2005) Sydney Multicenter Study of Parkinson\u2019s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20:190\u2013199. https:\/\/doi.org\/10.1002\/mds.20324","journal-title":"Mov Disord"},{"key":"6363_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.21803","volume":"23","author":"JSAM Reijnders","year":"2008","unstructured":"Reijnders JSAM, Ehrt U, Weber WEJ et al (2008) A systematic review of prevalence studies of depression in Parkinson\u2019s disease. Mov Disord 23:183\u2013189","journal-title":"Mov Disord"},{"key":"6363_CR8","doi-asserted-by":"publisher","unstructured":"Marsh L (2013) Depression and parkinson\u2019s disease: current knowledge topical collection on movement disorders. Curr Neurol Neurosci Rep 13(409).\u00a0https:\/\/doi.org\/10.1007\/s11910-013-0409-5","DOI":"10.1007\/s11910-013-0409-5"},{"key":"6363_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1600-0404.2007.00986.x","volume":"117","author":"SE P\u00e5lhagen","year":"2008","unstructured":"P\u00e5lhagen SE, Carlsson M, Curman E et al (2008) Depressive illness in Parkinson\u2019s disease - indication of a more advanced and widespread neurodegenerative process? Acta Neurol Scand 117:295\u2013304. https:\/\/doi.org\/10.1111\/j.1600-0404.2007.00986.x","journal-title":"Acta Neurol Scand"},{"key":"6363_CR10","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1212\/WNL.0000000000002898","volume":"87","author":"Z Goodarzi","year":"2016","unstructured":"Goodarzi Z, Mrklas KJ, Roberts DJ et al (2016) Detecting depression in Parkinson disease: a systematic review and meta-analysis. Neurol 87:426\u2013437","journal-title":"Neurol"},{"key":"6363_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/mds.20723","volume":"21","author":"L Marsh","year":"2006","unstructured":"Marsh L, McDonald WM, Cummings J et al (2006) Provisional diagnostic criteria for depression in Parkinson\u2019s disease: report of an NINDS\/NIMH Work Group. Mov Disord 21:148\u2013158","journal-title":"Mov Disord"},{"key":"6363_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/mdc3.12507","volume":"4","author":"SE Starkstein","year":"2017","unstructured":"Starkstein SE, Brockman S (2017) Management of depression in Parkinson\u2019s disease: a systematic review. Mov Disord Clin Pract 4:470\u2013477","journal-title":"Mov Disord Clin Pract"},{"key":"6363_CR13","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1212\/01.WNL.0000268695.63392.10","volume":"69","author":"B Ravina","year":"2007","unstructured":"Ravina B, Camicioli R, Como PG et al (2007) The impact of depressive symptoms in early Parkinson disease. Neurol 69:342\u2013347. https:\/\/doi.org\/10.1212\/01.WNL.0000268695.63392.10","journal-title":"Neurol"},{"key":"6363_CR14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0000000000000801","volume":"83","author":"P De La Riva","year":"2014","unstructured":"De La Riva P, Smith K, Xie SX, Weintraub D (2014) Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurol 83:1096\u20131103. https:\/\/doi.org\/10.1212\/WNL.0000000000000801","journal-title":"Neurol"},{"key":"6363_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1353-8020(01)00015-3","volume":"8","author":"LM Shulman","year":"2002","unstructured":"Shulman LM, Taback RL, Rabinstein AA, Weiner WJ (2002) Non-recognition of depression and other non-motor symptoms in Parkinson\u2019s disease. Park Relat Disord 8:193\u2013197. https:\/\/doi.org\/10.1016\/S1353-8020(01)00015-3","journal-title":"Park Relat Disord"},{"key":"6363_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/0891988717710335","volume":"30","author":"C Lachner","year":"2017","unstructured":"Lachner C, Armstrong MJ, Gruber-Baldini AL et al (2017) Discordance between physician assessment and patient-reported depressive symptoms in Parkinson disease. J Geriatr Psychiatry Neurol 30:191\u2013195. https:\/\/doi.org\/10.1177\/0891988717710335","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"6363_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.parkreldis.2015.04.018","volume":"21","author":"E Bomasang-Layno","year":"2015","unstructured":"Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S (2015) Antidepressive treatments for Parkinson\u2019s disease: a systematic review and meta-analysis. Park Relat Disord 21:833\u2013842","journal-title":"Park Relat Disord"},{"key":"6363_CR18","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","volume":"73","author":"XY Qin","year":"2016","unstructured":"Qin XY, Zhang SP, Cao C et al (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73:1316\u20131324. https:\/\/doi.org\/10.1001\/jamaneurol.2016.2742","journal-title":"JAMA Neurol"},{"key":"6363_CR19","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.3389\/fimmu.2018.02122","volume":"9","author":"X Chen","year":"2018","unstructured":"Chen X, Hu Y, Cao Z et al (2018) Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer\u2019s disease, Parkinson\u2019s disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Front Immunol 9:2122. https:\/\/doi.org\/10.3389\/fimmu.2018.02122","journal-title":"Front Immunol"},{"key":"6363_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","volume":"71","author":"MB Howren","year":"2009","unstructured":"Howren MB, Lamkin DM, Suls J (2009) Associations of depression with c-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 71:171\u2013186. https:\/\/doi.org\/10.1097\/PSY.0b013e3181907c1b","journal-title":"Psychosom Med"},{"key":"6363_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati Y, Herrmann N, Swardfager W et al (2010) A meta-analysis of cytokines in major depression. Biol Psychiatry 67:446\u2013457. https:\/\/doi.org\/10.1016\/j.biopsych.2009.09.033","journal-title":"Biol Psychiatry"},{"key":"6363_CR22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jad.2013.06.004","volume":"150","author":"V Valkanova","year":"2013","unstructured":"Valkanova V, Ebmeier KP, Allan CL (2013) CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 150:736\u2013744","journal-title":"J Affect Disord"},{"key":"6363_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/acps.12698","volume":"135","author":"CA K\u00f6hler","year":"2017","unstructured":"K\u00f6hler CA, Freitas TH, Maes M et al (2017) Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 135:373\u2013387. https:\/\/doi.org\/10.1111\/acps.12698","journal-title":"Acta Psychiatr Scand"},{"key":"6363_CR24","doi-asserted-by":"publisher","unstructured":"Ng A, Tam WW, Zhang MW et al (2018) IL-1\u03b2, IL-6, TNF- \u03b1 and CRP in elderly patients with depression or Alzheimer\u2019s disease: systematic review and meta-analysis. Sci Rep 8:12050. https:\/\/doi.org\/10.1038\/s41598-018-30487-6","DOI":"10.1038\/s41598-018-30487-6"},{"key":"6363_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.bbi.2019.06.015","volume":"81","author":"D Enache","year":"2019","unstructured":"Enache D, Pariante CM, Mondelli V (2019) Markers of central inflammation in major depressive disorder: a systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun 81:24\u201340","journal-title":"Brain Behav Immun"},{"issue":"1","key":"6363_CR26","doi-asserted-by":"publisher","first-page":"e0147601","DOI":"10.1371\/journal.pone.0147601","volume":"11","author":"PA Modesti","year":"2016","unstructured":"Modesti PA, Reboldi G, Cappuccio FP et al (2016) Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS One 11(1):e0147601. https:\/\/doi.org\/10.1371\/journal.pone.0147601","journal-title":"PLoS One"},{"issue":"10","key":"6363_CR27","doi-asserted-by":"publisher","first-page":"e47387","DOI":"10.1371\/journal.pone.0047387","volume":"7","author":"D Lindqvist","year":"2012","unstructured":"Lindqvist D, Kaufman E, Brundin L et al (2012) Non-motor symptoms in patients with Parkinson\u2019s disease \u2013 correlations with inflammatory cytokines in serum. PLoS One 7(10):e47387. https:\/\/doi.org\/10.1371\/journal.pone.0047387","journal-title":"PLoS One"},{"key":"6363_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbi.2013.07.007","volume":"33","author":"D Lindqvist","year":"2013","unstructured":"Lindqvist D, Hall S, Surova Y et al (2013) Cerebrospinal fluid inflammatory markers in Parkinson\u2019s disease\u2014associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 33:183\u2013189","journal-title":"Brain Behav Immun"},{"key":"6363_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-31517-z","volume":"8","author":"S Hall","year":"2018","unstructured":"Hall S, Janelidze S, Surova Y et al (2018) Cerebrospinal fluid concentrations of inflammatory markers in Parkinson\u2019s disease and atypical parkinsonian disorders. Sci Rep 8:1\u20139. https:\/\/doi.org\/10.1038\/s41598-018-31517-z","journal-title":"Sci Rep"},{"key":"6363_CR30","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00415-009-5353-6","volume":"257","author":"S P\u00e5lhagen","year":"2010","unstructured":"P\u00e5lhagen S, Qi H, M\u00e5rtensson B et al (2010) Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson\u2019s disease and major depression. J Neurol 257:524\u2013532. https:\/\/doi.org\/10.1007\/s00415-009-5353-6","journal-title":"J Neurol"},{"key":"6363_CR31","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00702-019-02096-8","volume":"126","author":"D Santos-Garc\u00eda","year":"2019","unstructured":"Santos-Garc\u00eda D, de Deus FT, Su\u00e1rez Castro E et al (2019) High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson\u2019s disease patients. J Neural Transm 126:1599\u20131608. https:\/\/doi.org\/10.1007\/s00702-019-02096-8","journal-title":"J Neural Transm"},{"key":"6363_CR32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/JPD-191699","volume":"9","author":"HF Green","year":"2019","unstructured":"Green HF, Khosousi S, Svenningsson P (2019) Plasma IL-6 and IL-17A Correlate with severity of motor and non-motor symptoms in Parkinson\u2019s disease. J Parkinsons Dis 9:705\u2013709. https:\/\/doi.org\/10.3233\/JPD-191699","journal-title":"J Parkinsons Dis"},{"key":"6363_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00702-018-1857-5","volume":"125","author":"B Vesel\u00fd","year":"2018","unstructured":"Vesel\u00fd B, Dufek M, Thon V et al (2018) Interleukin 6 and complement serum level study in Parkinson\u2019s disease. J Neural Transm 125:875\u2013881","journal-title":"J Neural Transm"},{"key":"6363_CR34","doi-asserted-by":"publisher","first-page":"574776","DOI":"10.3389\/fnagi.2020.574776","volume":"12","author":"T Lian","year":"2020","unstructured":"Lian T, Guo P, Zhang Y et al (2020) Parkinson\u2019s disease with depression: the correlations between neuroinflammatory factors and neurotransmitters in cerebrospinal fluid. Front Aging Neurosci 12:574776","journal-title":"Front Aging Neurosci"},{"key":"6363_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1023\/a:1015120930920","volume":"133","author":"MV Selikhova","year":"2002","unstructured":"Selikhova MV, Kushlinskii NE, Lyubimova NV, Gusev EI (2002) Impaired production of plasma interleukin-6 in patients with Parkinson\u2019s disease. Bull Exp Biol Med 133:81\u201383. https:\/\/doi.org\/10.1023\/a:1015120930920","journal-title":"Bull Exp Biol Med"},{"key":"6363_CR36","first-page":"474","volume":"51","author":"M Menza","year":"2010","unstructured":"Menza M, DeFronzo DR, Marin H et al (2010) The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson\u2019s disease. Psychosom J Consult Liaison Psychiatry 51:474\u2013479","journal-title":"Psychosom J Consult Liaison Psychiatry"},{"key":"6363_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00702-010-0535-z","volume":"118","author":"S Hassin-Baer","year":"2011","unstructured":"Hassin-Baer S, Cohen OS, Vakil E et al (2011) Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson\u2019s disease? J Neural Transm 118:539\u2013543","journal-title":"J Neural Transm"},{"key":"6363_CR38","doi-asserted-by":"publisher","first-page":"903796","DOI":"10.1155\/2014\/903796","volume":"2014","author":"NP Rocha","year":"2014","unstructured":"Rocha NP, Scalzo PL, Barbosa IG et al (2014) Cognitive status correlates with CXCL10\/IP-10 levels in Parkinson\u2019s disease. Parkinsons Dis 2014:903796. https:\/\/doi.org\/10.1155\/2014\/903796","journal-title":"Parkinsons Dis"},{"key":"6363_CR39","first-page":"3853","volume":"20","author":"X-M Wang","year":"2016","unstructured":"Wang X-M, Zhang Y-G, Li A-L et al (2016) Relationship between levels of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with Parkinson\u2019s disease. Eur Rev Med Pharmacol Sci 20:3853\u20133856","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"6363_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cellimm.2018.02.011","volume":"327","author":"MN Karpenko","year":"2018","unstructured":"Karpenko MN, Vasilishina AA, Gromova EA et al (2018) Interleukin-1\u03b2, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-\u03b1 levels in CSF and serum in relation to the clinical diversity of Parkinson\u2019s disease. Cell Immunol 327:77\u201382. https:\/\/doi.org\/10.1016\/j.cellimm.2018.02.011","journal-title":"Cell Immunol"},{"key":"6363_CR41","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16:448\u2013457","journal-title":"Nat Immunol"},{"key":"6363_CR42","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1523\/JNEUROSCI.2830-13.2014","volume":"34","author":"IL Campbell","year":"2014","unstructured":"Campbell IL, Erta M, Lim SL et al (2014) Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci 34:2503\u20132513. https:\/\/doi.org\/10.1523\/JNEUROSCI.2830-13.2014","journal-title":"J Neurosci"},{"key":"6363_CR43","first-page":"237","volume":"65","author":"SM Nehring","year":"2021","unstructured":"Nehring SM, Goyal A, Bansal P, Patel BC (2021) C reactive protein StatPearls 65:237\u2013244","journal-title":"C reactive protein StatPearls"},{"key":"6363_CR44","doi-asserted-by":"publisher","unstructured":"Qiu X, Xiao Y, Wu J et al (2019) C-reactive protein and risk of Parkinson\u2019s disease: a systematic review and meta-analysis. Front Neurol 10:384. https:\/\/doi.org\/10.3389\/fneur.2019.00384","DOI":"10.3389\/fneur.2019.00384"},{"key":"6363_CR45","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1017\/S0033291719001454","volume":"49","author":"EF Osimo","year":"2019","unstructured":"Osimo EF, Baxter LJ, Lewis G et al (2019) Prevalence of low-grade inflammation in depression: a systematic review and meta-Analysis of CRP levels. Psychol Med 49:1958\u20131970","journal-title":"Psychol Med"},{"key":"6363_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.placenta.2008.10.012","volume":"30","author":"S Haider","year":"2009","unstructured":"Haider S, Kn\u00f6fler M (2009) Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta 30:111\u2013123. https:\/\/doi.org\/10.1016\/j.placenta.2008.10.012","journal-title":"Placenta"},{"key":"6363_CR47","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","volume":"75","author":"I Peter","year":"2018","unstructured":"Peter I, Dubinsky M, Bressman S et al (2018) Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol 75:939\u2013946. https:\/\/doi.org\/10.1001\/jamaneurol.2018.0605","journal-title":"JAMA Neurol"},{"key":"6363_CR48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/J.JAD.2011.08.003","volume":"139","author":"Y Liu","year":"2012","unstructured":"Liu Y, Ho RC-M, Mak A (2012) Interleukin (IL)-6, tumour necrosis factor alpha (TNF-\u03b1) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 139:230\u2013239. https:\/\/doi.org\/10.1016\/J.JAD.2011.08.003","journal-title":"J Affect Disord"},{"key":"6363_CR49","doi-asserted-by":"crossref","unstructured":"Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 21(12):1696\u20131709.","DOI":"10.1038\/mp.2016.3"},{"key":"6363_CR50","doi-asserted-by":"publisher","unstructured":"Chen J, Liu X, Zhong Y (2020) Interleukin-17A: the key cytokine in neurodegenerative diseases. Front Aging Neurosci 12:566922. https:\/\/doi.org\/10.3389\/FNAGI.2020.566922","DOI":"10.3389\/FNAGI.2020.566922"},{"key":"6363_CR51","doi-asserted-by":"publisher","unstructured":"Storelli E, Cassina N, Rasini E et al (2019) Do Th17 lymphocytes and IL-17 contribute to Parkinson\u2019s disease? A systematic review of available evidence. Front Neurol 10:13. https:\/\/doi.org\/10.3389\/FNEUR.2019.00013","DOI":"10.3389\/FNEUR.2019.00013"},{"key":"6363_CR52","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.bbi.2019.07.026","volume":"81","author":"Z Liu","year":"2019","unstructured":"Liu Z, Qiu AW, Huang Y et al (2019) IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson\u2019s disease. Brain Behav Immun 81:630\u2013645. https:\/\/doi.org\/10.1016\/j.bbi.2019.07.026","journal-title":"Brain Behav Immun"},{"key":"6363_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbi.2017.08.001","volume":"69","author":"E Beurel","year":"2018","unstructured":"Beurel E, Lowell JA (2018) Th17 cells in depression. Brain Behav Immun 69:28\u201334","journal-title":"Brain Behav Immun"},{"key":"6363_CR54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/EJN.14636","volume":"53","author":"C Nothdurfter","year":"2021","unstructured":"Nothdurfter C, Milenkovic VM, Sarubin N et al (2021) The cytokine IL-17A as a marker of treatment resistance in major depressive disorder? Eur J Neurosci 53:172\u2013182. https:\/\/doi.org\/10.1111\/EJN.14636","journal-title":"Eur J Neurosci"},{"key":"6363_CR55","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/ACPS.12730","volume":"135","author":"EY Bryleva","year":"2017","unstructured":"Bryleva EY, Keaton SA, Grit J et al (2017) The acute-phase mediator serum amyloid A is associated with symptoms of depression and fatigue. Acta Psychiatr Scand 135:409\u2013418. https:\/\/doi.org\/10.1111\/ACPS.12730","journal-title":"Acta Psychiatr Scand"},{"key":"6363_CR56","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/J.BBI.2016.03.004","volume":"56","author":"FEP van Dooren","year":"2016","unstructured":"van Dooren FEP, Schram MT, Schalkwijk CG et al (2016) Associations of low grade inflammation and endothelial dysfunction with depression - the Maastricht Study. Brain Behav Immun 56:390\u2013396. https:\/\/doi.org\/10.1016\/J.BBI.2016.03.004","journal-title":"Brain Behav Immun"},{"key":"6363_CR57","doi-asserted-by":"publisher","unstructured":"Kurvits L, Reimann E, Kadastik-Eerme L et al (2019) Serum amyloid alpha is downregulated in peripheral tissues of Parkinson\u2019s disease patients. Front Neurosci 13:13. https:\/\/doi.org\/10.3389\/FNINS.2019.00013","DOI":"10.3389\/FNINS.2019.00013"},{"key":"6363_CR58","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/J.BBI.2012.06.001","volume":"26","author":"SA Hiles","year":"2012","unstructured":"Hiles SA, Baker AL, de Malmanche T et al (2012) A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behav Immun 26:1180\u20131188. https:\/\/doi.org\/10.1016\/J.BBI.2012.06.001","journal-title":"Brain Behav Immun"},{"key":"6363_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom10071017","volume":"10","author":"C Porro","year":"2020","unstructured":"Porro C, Cianciulli A, Panaro MA (2020) The regulatory role of IL-10 in neurodegenerative diseases. Biomolecules 10:1\u201315","journal-title":"Biomolecules"},{"key":"6363_CR60","doi-asserted-by":"publisher","unstructured":"Santaella A, Kuiperij HB, van Rumund A et al (2020) Inflammation biomarker discovery in Parkinson\u2019s disease and atypical parkinsonisms. BMC Neurol 20(1):26. https:\/\/doi.org\/10.1186\/S12883-020-1608-8","DOI":"10.1186\/S12883-020-1608-8"},{"key":"6363_CR61","doi-asserted-by":"publisher","unstructured":"Santaella A, Kuiperij HB, van Rumund A et al (2020) Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson\u2019s disease. npj Parkinsons Dis 6:21. https:\/\/doi.org\/10.1038\/s41531-020-00124-z","DOI":"10.1038\/s41531-020-00124-z"},{"key":"6363_CR62","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/S00702-019-02072-2","volume":"126","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou M, Wang Y et al (2019) Association of polymorphisms in the MCP-1 and CCR2 genes with the risk of Parkinson\u2019s disease. J Neural Transm 126:1465\u20131470. https:\/\/doi.org\/10.1007\/S00702-019-02072-2","journal-title":"J Neural Transm"},{"key":"6363_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2021.689939","volume":"13","author":"S Hu","year":"2021","unstructured":"Hu S, Huang S, Ma J et al (2021) Correlation of decreased serum pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide levels with non-motor symptoms in patients with Parkinson\u2019s disease. Front Aging Neurosci 13:1\u201310. https:\/\/doi.org\/10.3389\/fnagi.2021.689939","journal-title":"Front Aging Neurosci"},{"key":"6363_CR64","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/14656566.2019.1612877","volume":"20","author":"M Ryan","year":"2019","unstructured":"Ryan M, Eatmon CV, Slevin JT (2019) Drug treatment strategies for depression in Parkinson disease. Expert Opin Pharmacother 20:1351\u20131363","journal-title":"Expert Opin Pharmacother"},{"key":"6363_CR65","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/aws040","volume":"135","author":"S Anders","year":"2012","unstructured":"Anders S, Sack B, Pohl A et al (2012) Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele. Brain 135:1128\u20131140. https:\/\/doi.org\/10.1093\/brain\/aws040","journal-title":"Brain"},{"key":"6363_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2016.11.009","volume":"35","author":"J Borgonovo","year":"2017","unstructured":"Borgonovo J, Allende-Castro C, Laliena A et al (2017) Changes in neural circuitry associated with depression at pre-clinical, pre-motor and early motor phases of Parkinson\u2019s disease. Parkinsonism Relat Disord 35:17\u201324. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.11.009","journal-title":"Parkinsonism Relat Disord"},{"key":"6363_CR67","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/1570159X17666191016094857","volume":"18","author":"F Assogna","year":"2020","unstructured":"Assogna F, Pellicano C, Savini C et al (2020) Drug choices and advancements for managing depression in Parkinson\u2019s disease. Curr Neuropharmacol 18:277\u2013287. https:\/\/doi.org\/10.2174\/1570159X17666191016094857","journal-title":"Curr Neuropharmacol"},{"key":"6363_CR68","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12640-014-9467-y","volume":"26","author":"T Zaminelli","year":"2014","unstructured":"Zaminelli T, Gradowski RW, Bassani TB et al (2014) Antidepressant and antioxidative effect of ibuprofen in the rotenone model of Parkinson\u2019s disease. Neurotox Res 26:351\u2013362. https:\/\/doi.org\/10.1007\/s12640-014-9467-y","journal-title":"Neurotox Res"},{"key":"6363_CR69","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/J.NEUROSCIENCE.2015.05.030","volume":"300","author":"RM Santiago","year":"2015","unstructured":"Santiago RM, Tonin FS, Barbiero J et al (2015) The nonsteroidal antiinflammatory drug piroxicam reverses the onset of depressive-like behavior in 6-OHDA animal model of Parkinson\u2019s disease. Neurosci 300:246\u2013253. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2015.05.030","journal-title":"Neurosci"},{"key":"6363_CR70","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbi.2018.12.003","volume":"76","author":"M Campolo","year":"2019","unstructured":"Campolo M, Paterniti I, Siracusa R et al (2019) TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson\u2019s diseases in vivo model. Brain Behav Immun 76:236\u2013247. https:\/\/doi.org\/10.1016\/j.bbi.2018.12.003","journal-title":"Brain Behav Immun"},{"key":"6363_CR71","doi-asserted-by":"publisher","first-page":"300060520922449","DOI":"10.1177\/0300060520922449","volume":"48","author":"J Huang","year":"2020","unstructured":"Huang J, Hong W, Yang Z et al (2020) Efficacy of pramipexole combined with levodopa for Parkinson\u2019s disease treatment and their effects on QOL and serum TNF-\u03b1 levels. J Int Med Res 48:300060520922449. https:\/\/doi.org\/10.1177\/0300060520922449","journal-title":"J Int Med Res"},{"key":"6363_CR72","doi-asserted-by":"publisher","first-page":"105878","DOI":"10.1016\/j.clineuro.2020.105878","volume":"195","author":"R Daneshvar Kakhaki","year":"2020","unstructured":"Daneshvar Kakhaki R, Ostadmohammadi V, Kouchaki E et al (2020) Melatonin supplementation and the effects on clinical and metabolic status in Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial. Clin Neurol Neurosurg 195:105878. https:\/\/doi.org\/10.1016\/j.clineuro.2020.105878","journal-title":"Clin Neurol Neurosurg"},{"key":"6363_CR73","doi-asserted-by":"publisher","first-page":"e040527","DOI":"10.1136\/bmjopen-2020-040527","volume":"10","author":"JC Greenland","year":"2020","unstructured":"Greenland JC, Cutting E, Kadyan S et al (2020) Azathioprine immunosuppression and disease modification in Parkinson\u2019s disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ Open 10:e040527. https:\/\/doi.org\/10.1136\/bmjopen-2020-040527","journal-title":"BMJ Open"},{"key":"6363_CR74","doi-asserted-by":"crossref","unstructured":"Santos-Garc\u00eda D, Mir P, Cubo E et al (2016) COPPADIS-2015 (COhort of Patients with PArkinson\u2019s DIsease in Spain, 2015 a global \u2013clinical evaluations, serum biomarkers, genetic studies and neuroimaging\u2013 prospective, multicenter, non-interventional, long-term study on Parkinson\u2019s disease progressio. BMC Neurol 16:26.","DOI":"10.1186\/s12883-016-0548-9"},{"key":"6363_CR75","doi-asserted-by":"publisher","unstructured":"Picca A, Guerra F, Calvani R et al (2019) Mitochondrial-derived vesicles as candidate biomarkers in Parkinson\u2019s disease: rationale, design and methods of the EXosomes in PArkiNson Disease (EXPAND) Study. Int J Mol Sci 20(10):2373. https:\/\/doi.org\/10.3390\/ijms20102373","DOI":"10.3390\/ijms20102373"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06363-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06363-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06363-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T17:12:49Z","timestamp":1668445969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06363-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6363"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06363-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"26 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}}]}}